IP Library Granted Patent US 9,322,022
Granted Patent B2
US 9,322,022 · App. 14/520,318 · Granted Apr 26, 2016

Inhibition of DNA2 in fanconi anemia

Inventors: Kenneth Karanja (Pasadena, CA); Martin E. Budd (Pasadena, CA); Judith L. Campbell (Sierra Madre, CA)
Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
C12N15/1137C12N2310/14C12N2320/31C12Y306/04012
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,322,022
App. No.
14/520,318
Granted
Apr 26, 2016
Kind
B2
Abstract

Inhibition of DNA2 in Fanconi anemia (FA) cells remedies the over-resection of DNA, thereby stabilizing the FA cells. Inhibition of DNA2 in FA cells allows for safe treatment of cancers in FA patients, a decrease in the lethality of FA cells, a decrease in bone marrow failure of FA patients, and a means for decreasing the incidence of cancer for FA patients.

Claims (12)

1. A method of decreasing lethality of human Fanconi anemia cells or human Fanconi anemia-like cells, comprising inhibiting a human DNA2 gene, a human DNA2 transcript, and/or a human DNA2 protein, the inhibiting comprising:

using a viral vector to disrupt the DNA2 gene; and/or

using interfering RNA (RNAi) to inhibit translation of the DNA2 transcript; and/or

using acetylation and/or phosphorylation to inhibit post-translational modification of the DNA2 protein in the Fanconi anemia cells or the Fanconi anemia-like cells.

2. The method of claim 1 , wherein the inhibiting the DNA2 transcript comprises interfering RNA (RNAi) directed against the DNA2 transcript.

3. The method of claim 1 , wherein the Fanconi anemia cells or the Fanconi anemia-like cells are in vitro or in vivo.

4. The method of claim 1 , wherein the inhibiting comprises:

using the viral vector to disrupt the DNA2 gene; and/or

using the interfering RNA (RNAi) to inhibit translation of the DNA2 transcript.

5. The method of claim 1 , wherein the disruption of the DNA2 gene comprises deletion of exon 2.

6. The method of claim 1 , wherein the RNAi is shorthairpin RNA (shRNA).

7. The method of claim 6 , wherein the shRNA is targeted to exon 22 of the DNA2 gene.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 27, 2015
From: KARANJA, KENNETH; BUDD, MARTIN E.; CAMPBELL, JUDITH L.
To: CALIFORNIA INSTITUTE OF TECHNOLOGY
Reel/Frame 036187/0282 →
CONFIRMATORY LICENSE Recorded Oct 27, 2014
From: CALIFORNIA INSTITUTE OF TECHNOLOGY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034056/0623 →
Continuity (2)
Provisional Application 61893703 · Oct 21, 2013
Related Publication 20150111950A1 · Apr 23, 2015